Clinical feasibility of two-step streptavidin/111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis
- 107 Downloads
Streptavidin accumulates at sites of inflammation and infection as a result of increased capillary permeability. In addition to being utilised by bacteria for their own growth, biotin forms a stable, high-affinity non-covalent complex with avidin. The objective of this investigation was to determine the diagnostic performance of two-step streptavidin/111In-biotin imaging for evaluating patients with suspected vertebral osteomyelitis.
We evaluated 55 consecutive patients with suspected vertebral osteomyelitis (34 women and 21 men aged 27–86 years), within 2 weeks after the onset of clinical symptoms. Thirty-two of the patients underwent magnetic resonance imaging (MRI) and 24, computed tomography (CT). DTPA-conjugated biotin was radiolabelled by incubating 500 μg of DTPA-biotin with 111 MBq of 111In-chloride. Two-step scintigraphy was performed by first infusing 3 mg streptavidin intravenously, followed 4 h later by 111In-biotin. Imaging was begun 60 min later.
Streptavidin/111In-biotin scintigraphy was positive in 32/34 patients with spinal infection (94.12% sensitivity). The study was negative in 19/21 patients without infection (95.24% specificity). The corresponding results for MRI and CT were 54.17% and 35.29% (sensitivity), and 75% and 57.14% (specificity), respectively. All statistical parameters of diagnostic performance (Youden’s J index, kappa measure of agreement with correct classification, accuracy, sensitivity, specificity, positive likelihood and negative likelihood) were clearly better for streptavidin/111In-biotin scintigraphy than for either MRI or CT.
Streptavidin/111In-biotin scintigraphy is highly sensitive and specific for detecting vertebral osteomyelitis in the first 2 weeks after the onset of clinical symptoms, and is potentially very useful for guiding clinical decisions on instituting appropriate therapy.
KeywordsVertebral osteomyelitis Two-step streptavidin/111In-biotin scintigraphy Imaging modalities Diagnostic performance
- 1.Eismont FJ, Bohlman HH, Soni PL, Goldberg VM, Freeafer AA. Pyogenic and fungal vertebral osteomyelitis with paralysis. J Bone Joint Surg 1983;65A:19–29Google Scholar
- 2.Enzmann DR. Infection and inflammation. In: Enzmann DR, DeLaPaz RL, Rubin JB, eds. Magnetic resonance of the spine. St. Louis: Mosby; 1990:260–300Google Scholar
- 9.Ruther W, Hotze A, Moller F, Bockisch A, Heitzmann P, Biersack HJ. Diagnosis of bone and joint infection by leucocyte scintigraphy. A comparative study with 99mTc-HMPAO-labelled leucocytes, 99mTc-labelled antigranulocyte antibodies and 99mTc-labelled nano-colloid. Arch Orthop Trauma Surg 1990;110:26–32PubMedGoogle Scholar
- 12.Boerman OC, Rennen H, Oyen WJ, Corstens FH. Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med 2000;31:286–295Google Scholar
- 35.Chiesa R, Melissano G, Castellano R, Fernandez Zamora C, Astore D, Samuel A, Paganelli G, Fazio F, Grossi A. Avidin and 111In-labelled biotin scan: a new radioisotopic method for localising vascular graft infections. Eur J Endovasc Surg 1995;10:405–414Google Scholar
- 40.Siegel S. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956Google Scholar
- 45.Chinol M, Casalini P, Maggiolo M, Canevari S, Omodeo ES, Caliceti P, Veronese FM, Cremonesi M, Chiolerio F, Nardone E, Siccardi AG, Paganelli G. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer 1998;78:189–197PubMedGoogle Scholar